This review article focuses on common lower respiratory infections (LRIs) in indigenous populations in both developed and developing countries, where data is available. Indigenous populations across the world share some commonalities including poorer health and socioeconomic disadvantage compared with their nonindigenous counterparts. Generally, acute and chronic respiratory infections are more frequent and more severe in both indigenous children and adults, often resulting in substantial consequences including higher rates of bronchiectasis and poorer outcomes for patients with chronic obstructive pulmonary disease (COPD). Risk factors for the development of respiratory infections require recognition and action. These risk factors include but are not limited to socio-economic factors (e.g. education, household crowding and nutrition), environmental factors (e.g. smoke exposure and poor access to health care) and biological factors. Risk mitigation strategies should be delivered in a culturally appropriate manner and targeted to educate both individuals and communities at risk. Improving the morbidity and mortality of respiratory infections in indigenous people requires provision of best practice care and awareness of the scope of the problem by healthcare practitioners, governing bodies and policy makers.
INTRODUCTION
Indigenous people, sometimes also referred to as tribal people, first people or native people, constitute~5% of the world's population. 1 The United Nations estimates that there are >370 million indigenous people worldwide living in more than 70 countries.
2 Indigenous people are often described to be the offspring of those who have inhabited a country or geographical area prior to the arrival of people of a differing culture or ethnic background into that area. In many cases, the new arrivals achieved dominance via conquest or occupation. 2 The definition of 'indigenous' varies from country to country. Generally, indigenous people identify themselves as such and present in lower numbers within the overall population than their non-indigenous counterparts. Indigenous people retain unique traditions, social and cultural traits which distinguish their population and differentiate them from others in the society in which they live. 2 Examples of indigenous populations include Australian Aboriginal and Torres Strait Islanders, New Zealand (NZ) M aori, Arctic Inuits, Native Americans, hunters-gatherers in the Amazon, tribal peoples in the Philippines and traditional pastoralists such as the Maasai in East Africa. 3 Globally, indigenous populations often experience disproportionate levels of educational, employment, social disadvantage, poorer health outcomes and lower life expectancies than their nonindigenous countrymen. 4, 5 For the purpose of this review, indigenous people are defined as per the publications referenced in this article. We divided indigenous populations into those from affluent (e.g. Australia, NZ, USA and Canada) and non-affluent countries, as each group shares similar trends. The distinction based on affluence follows the world Gross Domestic Product rankings. 6 It is beyond the scope of this article to include detailed definitions, aetiology or specific treatments of conditions. Pleural infections are also not discussed. This review will focus on the disparity encountered by indigenous populations in relation to lower respiratory infections (LRIs) and explore common trends in risk factors, prevention and treatment.
EPIDEMIOLOGY Overview of respiratory infections worldwide
Respiratory infections and chronic respiratory disease are responsible for a large proportion of the morbidity and mortality faced by indigenous people. 7 Lower respiratory infections are more frequent and more severe in indigenous people and rates of pneumonia, bronchiectasis and chronic obstructive pulmonary disease (COPD) in indigenous populations in developed countries more closely mirror or exceed rates reported in developing countries. [8] [9] [10] [11] However, this likely reflects the ability to capture data better in developed countries.
In children, including indigenous children, LRIs are of importance as they may be associated with longterm respiratory complications, 12 large disease burden and early mortality, and impact both the child and their family. Globally, acute LRIs (ALRIs) including pneumonia represent the greatest (16%) single cause of death in children aged <5 years 13 and many of these deaths are preventable through education, improvement of living conditions and access to adequate health care.
14 Indigenous adults also experience high rates of chronic respiratory illness, which affects function and quality of life. Respiratory infection can also be an independent risk factor for other morbidity, for example cardiovascular disease 15, 16 and mortality. 17 However, much of the research published regarding LRIs in indigenous populations relates to children and less is known about the prevalence, impact and natural history of LRIs as the children move into adulthood.
Indigenous populations from affluent countries Australia
Indigenous Australians face social conditions and health status more comparable to those in developing countries. 12 Nationwide, respiratory disorders in indigenous Australians are the: (i) most common reason for general practice encounters and (ii) second most common cause for acute hospitalization. 5, 18 Acute and chronic respiratory diseases are almost 10 times more common in Australian indigenous than non-indigenous children. 12 The overall hospitalization rate for respiratory disease in indigenous children aged between 0 and 4 years is almost twice that of nonindigenous children. 5 The disproportionately high LRI hospitalization rate in indigenous children occurs irrespective of whether they reside in an urban, rural or remote setting. 12 Furthermore, compared with nonindigenous children, ALRIs are the most common cause of preventable death in infants, emergency medical retrievals from remote communities and hospitalizations amongst indigenous children aged <5 years. 19 Rates of bronchiolitis and pneumonia are particularly high in Australian indigenous children; for example, hospitalization rates for Western Australian indigenous children born between 1999 and 2000 for ALRIs, pneumonia and bronchiolitis were 7.5, 13.5 and 5.8 times greater, respectively, than that for non-indigenous children. 20 The incidence of bronchiolitis-associated hospitalization in indigenous Australian infants is particularly high; 190/1000 in Central Australia compared with 62/1000 in Native American infants. 21, 22 In the Northern Territory (NT), the Australian state with the greatest proportion of indigenous people, 20% of indigenous infants will be hospitalized at least once prior to their first birthday with an acute LRI 21 ; 7% will have ≥2 episodes and 4% radiologically confirmed lobar pneumonia. 21 The first episode of hospitalization for LRIs occurs very early in life in indigenous children; median age of 4.6 months for ALRI and mean of 8.1 months (95% CI: 7.7-8.5) for the first episode of radiologically confirmed pneumonia. 12, 21, 23 Indigenous Australian children hospitalized with pneumonia are 15 times more likely to develop bronchiectasis (OR: 15.2; 95% CI: 4.4-52.7), 24 and this risk increases further when pneumonia is recurrent or if the episodes are more severe. 24 At least 10 in every 10 000 indigenous infants in the NT develop bronchiectasis in their first year of life. 21 This rate is significantly higher than the rate of cystic fibrosis in Australia (3.6/10 000). 25 In addition to the elevated frequency of LRI hospitalizations, the severity of disease in indigenous children is also greater. In a study of children aged <2 years hospitalized in Darwin with bronchiolitis between 2005 and 2006, indigenous children (n = 80) compared with non-indigenous children (n = 21) had a longer duration of oxygen requirement (median = 3 and 0 days, respectively; P = 0.004), more antibiotic treatment (60% and 19%; P = 0.001), concurrent pneumonia (18% and 0%; P = 0.04) and longer hospital stay (median = 6 and 3 days; P = 0.001). 26 Using a severity scale ('mild', 'moderate' or 'severe'), 27 indigenous children experienced more severe illness than nonindigenous children (P < 0.001). 26 Indigenous children with LRIs are also likely to have higher rates of co-morbidities (e.g. malnutrition, anaemia and gastrointestinal illness) than non-indigenous children with the same respiratory disease. 28 A study evaluating indigenous infants aged <12 months admitted with an ALRI, ≥1 co-morbidities were present in 45% (1445/3227) of episodes (gastroenteritis = 832 (26%), anaemia = 896 (28%), malnutrition = 128 (4%)). 21 Concurrent comorbidities are particularly common in children with radiologically confirmed pneumonia; one study of 109 indigenous children hospitalized with radiological alveolar changes in Central Australia showed 51.5%, 37.3% and 29.8% of children to have anaemia, suppurative otitis media and diarrhoea, respectively. 29 Over 25% of indigenous Australian adults report having a respiratory disease, 5 with chronic respiratory disease presentations second only to renal dialysis as the most common reason for hospitalization. 25 Pneumonia is a significant contributor to respiratory morbidity and mortality among indigenous Australians; for example indigenous Australians are 5.5 times more likely to be hospitalized with pneumonia, and pneumonia accounts for~30% of respiratory-related deaths. 25 Whilst the most common aetiology remains Streptococcus pneumoniae, staphylococcal and melioidosis pneumonia are more common in indigenous patients. 30, 31 Indigenous Australians also have a higher annual incidence of tuberculosis (8.7/100 000 compared with 0.8/ 100 000 in non-indigenous Australians) 25 and mortality rate ratio (24-28 times higher). 25 Bronchiectasis is also common in adult indigenous Australians. Central Australian Indigenous adults with bronchiectasis are young (23% are aged <30 years) 32 and die prematurely (in their fourth decade of life). 32 Overall hospitalization separation data are 4-5 times higher for bronchiectasis and COPD in indigenous Australians and mortality from bronchiectasis and COPD/asthma is 6 and 3 times higher, respectively, for indigenous people compared with other populations in Australia. 25 Available data for respiratory disease in indigenous Australians likely under-represents the true disease burden, as many patients with respiratory illness remain undiagnosed, are untreated or are treated in remote communities with limited access to integrated medical records.
New Zealand
M aori and Pacific Islanders are disproportionately and consistently more affected by LRIs than nonindigenous New Zealanders. The overall respiratory hospitalization rate is elevated in M aori and Pacific Islanders. 33, 34 In a study of South Auckland M aori and Pacific Islander children aged <2 years, hospitalization rate for ALRIs was significantly higher at 177/1000 compared with the national rate of 103/1000. 35 Furthermore, hospitalization rates for bronchiolitis and pneumonia in children and bronchiectasis and COPD in adults are higher in M aori and Pacific Islanders when compared with those from a non-M aori/Pacific/Asian (non-MPA) background (Table 1) . 34 Mortality rates for pneumonia in M aori and Pacific Islander children were 5.4 and 6.2 times higher, respectively, compared with non-MPA children. 34 These differences were greatest in children aged <5 years. 34 Similar to Australian data, ongoing respiratory morbidity amongst M aori and Pacific Islander children posthospitalization for LRIs is elevated. In Auckland, 74% of the 81 children followed up at 10-14 months following hospitalization had a wet cough, crackles on chest auscultation or chest X-ray (CXR) abnormalities. 35 The overall incidence of new cases of bronchiectasis in children aged <15 years in NZ was~3.7/100 000 during 2001-2002. 36 In Pacific and M aori children, the incidence was significantly elevated at a rate of 17.8 and 4.8/100 000/year, respectively (compared with 1.5/ 100 000/year in NZ children of European descent). 36 The median age at diagnosis was 5.2 years with the majority having had symptoms for >2 years. 36 In adults, bronchiectasis prevalence is higher in M aori and Pacific Islanders compared with non-MPA adults. 25 In a 2014 report, the hospitalization rate for bronchiectasis was highest in the elderly (98.8 hospitalizations per . Permission implied provided due acknowledgement has been given to original reference.
MPA, M aori/Pacific/Asian. 100 000 people aged >65 years). 34 The mortality rate for COPD was highest in the M aori population (199.9 deaths per 100 000 people/year). 34 This was 2.22 (95% CI: 2.04-2.41) times greater than the rate of 90.2 for the non-MPA population. 34 Pacific Islander rates were not significantly different from the non-MPA rates. 34 Both bronchiectasis hospitalizations and COPD mortality rates showed strong socio-economic disparity. 34 
United States of America
Native Americans constitute >500 American Indian (AI) and Alaska Native (AN) tribes. 7 Rates of LRIs for AI and AN children aged <5 years in the Alaskan and Southwest regions are at least double and triple (41.2 and 28.0 per 1000/year, respectively) the rates reported in the USA overall (13.8 per 1000/year) between 1998 and 2008. 37 In AI and AN infants, LRI rates were significantly elevated at 136.4 and 82.4 per 1000/year, respectively, in comparison to the general infant population of the USA (37.1 per 1000/year; 95% CI: 34.3-40.0). 37 Between 2007 and 2009, the overall annual ageadjusted hospitalization rate for infectious diseases was higher for AN people (2126/100 000) than for the general US population (1628/100 000, 95% CI: 1610-1646), with LRIs accounting for the highest percentage (39%) of all infectious disease hospitalizations amongst AN people. 8 In another study, the LRI hospitalization rate in AI/AN children was almost twice that of other children (116.1 vs 63.2/1000, respectively). 38 Respiratory syncytial virus (RSV) infection is a leading cause of hospitalizations amongst infants in the USA, and AI/AN infants living in the Southwest and Alaskan regions are at particularly high risk of RSV infection and bronchiolitis requiring hospitalization compared with the non-indigenous population. 39, 40 Chronic suppurative lung disease is also more prevalent in AN children with 1 in every 63-68 children (~1500/100 000) being affected. 41 In a study assessing mortality from pneumonia and influenza between 1990-1999 and 2000-2009, death rates for AI/AN adults in both periods were significantly higher compared with non-indigenous people. 42 Tuberculosis disproportionately affects the AN people compared with the general population. 7 The severity of disease in the AN population is also greater, with the mortality rate being~6 times higher and the annual incidence is almost twice that the of the overall US population. 7 
Canada
Indigenous populations of Canada include the First Nations (FN), Innu/Inuit and Metis people. Canadian FN and Inuit children are at a disproportionately high risk of LRIs such as bronchiolitis, pneumonia and tuberculosis, 43 with bronchiolitis being particularly more frequent and severe. For example, the rate of RSV bronchiolitis requiring hospitalization was 484/1000 in Inuit infants living in Baffan compared with 27/1000 in non-indigenous infants living in other parts of Canada and the USA. 39, 43 In a study comparing hospitalization rates due to pneumonia in children and adults between Innu/Inuit communities in Labrador and a sample of nonindigenous communities on the Northern Peninsula of Newfoundland in Canada, hospitalization rate for community-acquired pneumonia for the Innu/Inuit communities was~4 times greater than the rate for residents of non-Aboriginal communities (11.6/1000 vs 3.0/1000 population, respectively; P < 0.01 × 10 −4 ). 44 This discrepancy was consistent across all age groups. Another study in Alberta showed that the hospitalization rate for community-acquired pneumonia is~5 times greater amongst FN peoples compared with the general population (22/1000 (95% CI: 20.7-23.6) vs 4.4/ 1000 (95% CI: 4.4-4.5), respectively). 45 Furthermore, the rate of hospitalization for respiratory illness in Manitoba and Saskatchewan was 3.6 and 3.9 times greater, respectively, in indigenous than in nonindigenous people. 44, 46 Tuberculosis rates remain significantly elevated in FN and Inuit people. In 2014, the tuberculosis incidence rate was 20.4/100 000 population in Canadianborn indigenous people compared with an incidence rate of 0.6/100 000 in the general population. 47 
Indigenous populations from non-affluent countries
There are indigenous populations in many non-affluent countries around the world, including the tribal people from Philippines, Maasai in East Africa, Saami of Northern Europe, Mayas in Guatemala and the Aymaras in Bolivia.
2, 3 There is a paucity of literature published in English regarding the prevalence and morbidity of LRIs for these peoples and this discussion will be confined to general trends.
Access to adequate health care and understanding of disease may be more limited in poorer countries. 48 People in non-affluent countries are likely to have more risk factors for infections than those in affluent settings, including a greater number of co-morbidities and increased exposure to passive smoke, biomass fuels and indoor and outdoor air pollutants. 49 COPD is most commonly caused by tobacco smoke but exposure to biomass fuels via unflued indoor cooking and air pollutants is an important contributor to COPD particularly in developing countries. Biomass fuels, in the form of wood, dung and crop residues, are typically burnt indoors in open fires or poorly functioning stoves, producing localized pollution, particularly to women. 49 Other factors such as malnutrition and overcrowding further increases the risk of respiratory infections. 50 Respiratory infections are a common cause of COPD exacerbations and patients with nonsmoking-related COPD have higher rates of pneumonia and hospitalization for COPD. 51 
RISK FACTORS FOR RESPIRATORY INFECTIONS IN INDIGENOUS POPULATIONS, LIKELY COMMON TO ALL
Globally, indigenous populations are often displaced from their ancestral lands and are more likely to live in poverty with poor living conditions, lower education levels and higher unemployment rates. 4 These aspects contribute to poorer health and increased infection rates; however, precisely defining the level of risks associated with these factors is difficult and risk factors are likely to vary by population and geography. Whilst some comparative data between indigenous and nonindigenous people are available, there are few studies within the indigenous communities themselves, which increase the difficulty of attributing risk.
A combined study evaluating chronic suppurative lung disease and bronchiectasis in Australia, NZ and Alaska showed that in all regions there were significant disparities in risk factors and poverty indices between the respective indigenous and non-indigenous populations (Table 2) . 52 
Socio-economic risk factors
Socio-economic risk factors likely contribute towards the increased risk of LRIs in indigenous people. 53 In particular, housing conditions play a substantial role in determining the risk of respiratory infections. A higher proportion of indigenous people live in overcrowded dwellings with poor ventilation. 54 Overcrowding increases transmission of respiratory infections 55 and increases the risk of exposure to tobacco smoke 56 and other infectious co-factors 57 (e.g. secondary bacteria with viral infections). Overcrowding may perpetuate LRIs as poor housing conditions contribute to incomplete resolution of LRIs. 29, 58 A metaanalysis found that household crowding is associated with increased risk of pneumonia/LRIs (OR = 1.69, 95% CI: 1.34-2.13 and rate ratio: 1.36, 95% CI: 1.09-1.69), Haemophilus influenzae Type B (Hib) infection (OR = 1.74, 95% CI: 1.27-2.37) and RSV bronchiolitis when cohort (4.44, 95% CI: 2.45-8.04) and case-control data (OR = 1.31, 95% CI: 0.85-2.01) were considered separately. 59 A rural Alaskan study described that in children aged <3 years living in a household with ≥6 people or <4 rooms were significantly associated with increased risk of hospitalization with LRIs compared with matched controls. 60 A Brazilian study revealed similar findings.
61 Case-control studies in the USA show that household crowding 62 and large household size 63 are risk factors for Hib infection. RSV has been found to be linked with crowded homes in Norway 64 and Alaska. 40 In cooler climates such as NZ, cold, damp and mouldy houses can also be associated with increased risk of LRIs. 65, 66 Protective factors include having ≥2 sinks or more rooms in the house. 60 Nevertheless, cultural practices of extended families living together may also be a co-factor in overcrowded living conditions. Malnutrition, inadequate access to clean water and poor sanitation are common amongst indigenous populations, affecting general health and susceptibility to infection. Comorbidities such as diabetes mellitus is more prevalent in indigenous populations 67 and is also a risk factor for LRIs. For example, diabetes is an independent risk factor for the development of melioidosis infection in the NT in Australia, 68 and persistence of tuberculosis amongst the AN indigenous population in the USA. 7 
Environmental risk factors Exposure to tobacco smoke and pollution
The link between childhood tobacco smoke exposure and respiratory infections and the association between active smoking and poorer lung health is now indisputable. 14, 69, 70 Whilst a review of tobacco smoking and exposure among indigenous populations is beyond the scope of this review, all aspects of tobacco smoking and exposure are higher among indigenous peoples. Additionally, many people in disadvantaged settings experience exposure to biomass combustion. 49 Use of woodstoves inside the home for heating and/or cooking has also been shown to be associated with an increased risk of LRIs in multiple studies. 43, 60 Geographical remoteness leading to poor access to health care
Geographical isolation and poor access to health care may hinder timely diagnosis and treatment of LRIs. For instance, in Australia and Canada, many indigenous people live in rural and remote regions, with low population density, higher service delivery costs, lack of transportation infrastructure and reduced access to health services. 71, 72 The remoteness and isolation of these communities can also result in low retention of health professionals, leading to inadequate access to medical care.
Biological risk factors
Although indigeneity itself may be a risk factor for the development of LRIs, not much data are available to verify this with certainty. Past studies have suggested that indigenous ethnicity and genetic predisposition may or may not be a contributing factor in itself for hospitalization with respiratory infections in children. 43, 73 Other risk factors
The discrepancy in disease burden between indigenous and non-indigenous people begins at conception. Lung development initiates in utero with the alveolar stage occurring from~36 weeks' gestation and continues until~7 years postnatally 74 and therefore the in utero environment and lung health in childhood can predict future respiratory morbidity. 75 Severe or recurrent acute respiratory infections early in life, particularly within the first 2 years (as this is when postnatal lung development is most important), are significant predeterminants of developing adult lung diseases such as COPD and bronchiectasis. 21, 76, 77 Indigenous infants have a higher prevalence of low birth weight and these children are~6 times more likely than children of normal birth weight to be hospitalized with ALRIs. 78 Suboptimal immunization coverage in infancy and childhood may be another risk factor for respiratory infections in indigenous children. 79, 80 Studies of the timeliness of immunization in indigenous children in the NT and Queensland in Australia found delayed immunization. 79, 80 The NT study noted that at 7, 13 and 18 months of age, only 45.2%, 49.5% and 81.2% of indigenous children had completed the recommended schedule, respectively, indicating significantly suboptimal immunization rates in the first years of life. 79 Lower education level and poor health literacy can lead to poorer self-care, consequently leading to delay in seeking medical assistance and lower adherence to treatment. Fear of western medicine, cultural unawareness by healthcare providers and language barriers may also defer/deter indigenous people from seeking help.
STRATEGIES IN OVERALL MANAGEMENT Prevention
Improving infant and child health, prevention of persistent or recurrent LRIs and prompt and effective treatment of infections is the cornerstone of reducing the burden of LRIs in indigenous populations. Therefore, prevention of respiratory disease commences at conception and interventions that reduce ALRIs in indigenous children would be expected to have both short-and long-term benefits.
Breastfeeding is protective against development of LRIs in babies including lowering RSV-associated hospitalization. 40 One study found that breastfeeding was a protective factor against the development of bronchiectasis later in life (OR: 0.2; 95% CI: 0.1-0.7). 24 Preventative measures to address environmental antecedents include smoking cessation and restricting passive (including in utero) smoke exposure, ensuring proper maintenance, sealing and ventilation of wood stoves and using heat recovery where possible. However, a recent cluster randomized controlled trial in rural Malawi did not show a reduction in childhood pneumonia when assigned an intervention comprising cleaner burning biomass-fuelled cook stoves (in comparison to continuation of open fire cooking), 81 highlighting the need for further studies evaluating effective strategies to reduce adverse effects of household air pollution.
Improving sanitation and hygiene practice/behaviour, modifying living conditions, enhancing nutrition and addressing co-morbidities will also assist in reducing the LRI burden.
In remote indigenous communities, the carers' ability to adopt some positive parenting behaviours is known to be restricted by limited knowledge, low levels of self-efficacy and barriers in the physical and social environment. 82 Improvements in these aspects are required to promote hygiene behaviours. Current evidence suggests that among disadvantaged groups, providing items to encourage simple preventive care (with distinct well-defined behavioural goals) can be effective. 83 Subsidizing the cost of required items can remove an economic barrier to undertaking the behaviour. However, for new behaviours to become habitual, enablers need to be continued or reinforced for the behaviour to persist. 84 Early recognition of those at risk of development of chronic lung disease requires education of indigenous people, primary healthcare providers and specialist clinicians. It also requires systems and training to ensure implementation of standard treatment protocols and early identification of people at risk. For example, in indigenous Australians, chronic cough is often 'normalized', in contrast to non-indigenous Australians. 85 Despite common assumptions, one NT study found extremely poor respiratory health knowledge amongst caregivers of indigenous children and that the use of culturally appropriate flipcharts could improve their knowledge. 86 Whether increased knowledge transcribes to improved health practices/behaviours and/or outcomes remains unknown.
Immunization has played a substantial role in reducing mortality across all age groups worldwide. The introduction of Hib vaccination in 1993 was associated with a >95% concurrent decline in notified cases of Hib disease including pneumonia. 87 Studies have demonstrated that Hib and pneumococcal conjugate vaccines can prevent between 20% and 37% of radiologically confirmed pneumonia in children aged <2 years. 88 A large population-based surveillance study in an AI population (Navajo, USA) between 1995 and 2006 showed that invasive pneumococcal disease secondary to serotypes covered by the vaccine was almost eliminated amongst Navajo of all ages since the availability of the 7-valent pneumococcal conjugate (PCV-7) vaccine. 89 However, the benefits from population-based vaccination programmes have not been universal. In the NT in Australia for instance, despite achieving a population PCV-7 vaccination coverage rate of~90%, the incidence of radiologically confirmed pneumonia has not significantly decreased. 90 Nevertheless, indigenous-specific national immunization guidelines exist. In Australia, the Australian National Immunisation Program recognizes indigeneity as a risk factor. Accordingly, the schedule of immunizations differ for indigenous and non-indigenous people 87 with regards to pneumococcal and influenza vaccines, for example.
Innovative public health measures and active engagement from indigenous people to be involved in their health care are required. Education of indigenous people and communities is vitally important for changes to occur over time. Involvement of indigenous liaison officers and increased leadership within communities themselves to instigate culturally appropriate prevention and control strategies are needed. 7 
Treatment approaches
Preventative strategies remain essential to reducing ALRIs. However, appropriate and timely medical assessment and management of respiratory infections in indigenous people is also extremely important. Extrapolation of treatment guidelines from affluent settings to indigenous populations can be challenging due to many reasons including confounding socioeconomic complexities, inequity of access to health care and poverty. Along with management of the specific condition, social, environmental and nutritional requirements also need to be addressed to interrupt the vicious cycle of poverty and illness.
Medical follow-up of indigenous patients can also be difficult. For a patient residing in a remote indigenous community for instance, a simple test such as a followup CXR after pneumonia can often involve a combination of lengthy air and ground transportation and overnight accommodation near the treating medical centre, leading to significant disruption to the patient's family along with a high financial burden. 29 Adaptive measures such as a pre-discharge CXR may be an alternative method to predict outcome in patients who are geographically isolated from health care. 29 A service perceived by carers to be culturally safe is likely to increase attendance for scheduled services. 91 Thus, a system's approach that incorporates culturesafe practices is required throughout primary, secondary and tertiary health centres.
Despite the challenges, indigenous patients should receive the same high-quality best practice treatment as their countrymen. Adaptation of best available evidence and applying this to indigenous patients, development of standard treatment protocols which are adhered to, training of clinical staff and improvement of clinical services are essential to ensure timely and appropriate treatment of LRIs in indigenous people.
RESEARCH PRIORITIES/GAPS
There are many clinical and research gaps in the pathogenesis and management of LRIs in indigenous children and adults. Some of these gaps and their rationale are highlighted in Table 3 .
Overall, the need for dedicated patient-focused and culturally appropriate research, targeted education and health promotion campaigns and directed interventions for indigenous populations is glaring. Collaboration between health professionals, patients, communities and governments is essential to reduce LRIs in indigenous populations and narrow this significant gap in social circumstances and health status.
CONCLUSION
Globally indigenous populations share many common traits, including poorer health and socio-economic disadvantage. Respiratory infections are generally more frequent and more severe in both indigenous children and adults, often leading to significant short-and longterm consequences. Risk factors for development of LRIs in indigenous people require early recognition and prompt action and preventative strategies to mitigate risk should be delivered in a culturally appropriate and targeted manner. Improving the outcome of LRIs in indigenous people requires increased awareness and provision of best practice care. ; however, by using locally relevant additions (such as indigenous status and a higher weighting for albumin), the predictive value of the score could be improved 92 Encourage International collaborations to collate worldwide data regarding LRIs
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Emerging groups such as the Australian Bronchiectasis Registry (ABR) and The European Bronchiectasis Registry (EMBARC) offer hope for both indigenous and non-indigenous patients with bronchiectasis as the disease is beginning to be mapped, for the first time, on a global level
